The a2 Milk Company has launched a second court challenge in as many months to a ruling from IP Australia, after rival Lion Dairy successfully opposed its bid to trade mark the phrase a2 milk.
Hytera can’t point the finger at Motorola for not alerting it to the alleged theft of the US telco’s source code by former employees sooner, as the first phase of the high stakes, high intrigue IP trial draws to a close.
IP Australia has rejected Dow AgriCulture’s bid to patent a smart pest control device, saying the invention lacks an inventive step.
IP boutique Spruson & Ferguson has lured former Phillips Ormonde Fitzpatrick patent attorney Ken Bolton to join the firm’s Sydney office as of counsel.
Ink cartridge reseller Calidad has been ordered to show evidence of its finances in support of its application to stay a Full Court judgment while it waits for the outcome of its special leave application to the High Court in a landmark patent infringement dispute with printer giant Seiko Epson.
The Australian federal government’s proposed legislation to abolish the innovation patent system, Australia’s second tier patent system, was introduced into parliament on July 25. Here, Griffith Hack’s Dr Malcolm Lyons and Dr Justin Sweetman tell you what you need to know about the Intellectual Property Laws Amendment (Productivity Commission Response Part 2 and Other Measures) Bill 2019.
US investment manager State Street Global Advisors claims it lost out on royalties when Maurice Blackburn commissioned an allegedly infringing replica of its iconic Fearless Girl statue in New York City, a marketing phenomenon that has been estimated to be valued at up to $38.6 million.
An appeal by gaming giant Aristocrat Technologies of an IP Australia ruling revoking four of its patents will head to trial in September ahead of outcomes in two high stakes cases over the patentability of computer software.
The important decision by the Full Court of the Federal Court in Calidad Pty Ltd v Seiko Epson Corporation clarifies the position on an area of law that, surprisingly, is still developing in Australia, namely the scope of the implied licence issuing from the sale of a patented product, writes Duncan Longstaff and Roshan Evans of Shelston IP.
US biotechnology firm Regeneron Pharmaceuticals has lost its opposition to a proposed patent by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.